Vitamin D Interactions

Phenobarbital is a strong inducer of liver enzymes that speed the breakdown of vitamin D, so long-term use can lower 25-hydroxyvitamin D and, over months to years, contribute to softened bones (osteomalacia in adults, rickets in children) and higher fracture risk. Children and older or housebound adults are most vulnerable. The drop in vitamin D is well documented; some experimental work also suggests phenobarbital may slow vitamin D activation, though that mechanism rests on animal and cell studies. Have vitamin D and bone-related labs reviewed and discuss ongoing vitamin D with your doctor or pharmacist.

Phenytoin induces the liver enzymes that break down vitamin D, accelerating clearance of 25-hydroxyvitamin D and lowering circulating levels over time. The downstream result can be reduced calcium absorption, a compensatory rise in parathyroid hormone, and an increased risk of softened bones (osteomalacia) and fractures with long-term use.

Carbamazepine activates the pregnane X receptor and induces the liver enzymes (including CYP3A4 and CYP24A1) that break down vitamin D, accelerating the clearance of 25-hydroxyvitamin D into inactive metabolites. A meta-analysis and observational studies consistently show lower 25(OH)D in long-term carbamazepine users, along with a secondary-hyperparathyroidism pattern and reduced bone density that raises fracture risk over years of therapy.

Glucocorticoids such as prednisone speed up the breakdown of vitamin D and blunt vitamin D-driven calcium absorption at the gut, which contributes to bone loss. Population data link oral steroid use to a higher rate of severe vitamin D deficiency, so vitamin D plus adequate calcium is a standard part of long-term steroid care.

Methylprednisolone (a glucocorticoid) speeds the breakdown of vitamin D and weakens vitamin D-driven intestinal calcium absorption. Over continued therapy this lowers vitamin D status and contributes to glucocorticoid-induced bone loss.

Vitamins A and D share the RXR receptor partner, but the best human evidence shows high-dose preformed vitamin A can blunt vitamin D's effect on calcium and bone — the relationship is competitive, not a proven beneficial synergy. At ordinary dietary or multivitamin levels there is no meaningful problem.

Vitamin D's active metabolite (calcitriol) can mildly induce CYP3A4, the liver enzyme that breaks down atorvastatin, which can lower atorvastatin blood levels. Despite this, the cholesterol-lowering effect appears largely preserved, so the combination is generally fine. Strip precise dose targets and review high-dose vitamin D regimens with your doctor or pharmacist.

Higher caffeine intake is weakly associated with lower vitamin D status. In cell studies caffeine reduces vitamin D receptor (VDR) expression in bone-forming cells, and a large NHANES cross-sectional analysis links higher caffeine intake to a modestly greater chance of low serum 25-hydroxyvitamin D. The effect is small and matters most for people who already have low vitamin D, low calcium intake, and high bone-loss risk (for example, postmenopausal women). It is not an absorption-level interaction, so there is no need to separate the timing of a vitamin D supplement from coffee.

Vitamin D supplementation genuinely lowers parathyroid hormone (PTH) by raising serum calcium and active vitamin D, so a PTH test drawn after recent vitamin D can read below the patient's true untreated baseline. This is a real physiologic effect and a timing/interpretation issue, not an assay artifact or a dangerous interaction.

Fat from omega-3 supports absorption of the fat-soluble vitamin D

Magnesium helps activate and support the function of vitamin D; low magnesium can reduce the effectiveness of vitamin D supplementation. This is a beneficial nutrient synergy rather than a harmful interaction.

Vitamin D and vitamin K2 act synergistically on calcium metabolism: vitamin D increases calcium absorption while vitamin K2 activates osteocalcin and matrix Gla protein to direct calcium into bone and away from soft tissue. The main caution is for people taking warfarin.

Vitamin D and probiotics act on overlapping pathways in the gut. Vitamin D supports vitamin D receptor (VDR) activity in the intestinal lining, which probiotics rely on for their anti-inflammatory and barrier-strengthening effects, while some probiotic strains appear to modestly raise circulating vitamin D. Randomized trials suggest combined supplementation can outperform either alone for some inflammatory and gut-barrier endpoints, though the evidence base is still limited.